SWOG clinical trial number
SWOG-8897
Comparison of Adjuvant Chemotherapy With or Without Endocrine Therapy in High-Risk, Node Negative Breast Cancer Patients, and a Natural History Follow-up Study in Low-Risk Node Negative Patients (to initially low risk patients)
100% Accrual
Accrual
100%
Closed
100% Accrual
Accrual
100%
Published
Abbreviated Title
CMF vs. CAF ± Tamoxifen in High-Risk, Node Neg.
Treatment
Tamoxifen
CAF
CMF
2014
Association between BMI at treatment initiation and cancer survival across multiple SWOG trials
H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster
2010
Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer [PMC3058716; PMID21169260]
S Yao;W Barlow;K Albain;JY Choi;H Zhao;R Livingston;W Davis;J Rae;IT Yeh;L Hutchins;P Ravdin;S Martino;A Lyss;CK Osborne;M Abeloff;G Hortobagyi;DF Hayes;C Ambrosone Clinical Cancer Research 16:6169-6176;
Manganese superoxide dismutase polymorphism treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer [PMID 20309628; PMC2968705]
S Yao;W Barlow;K Albain;JY Choi;H Zhao;R Livingston;W Davis;J Rae;IT Yeh;L Hutchins;P Ravdin;S Martino;A Lyss;CK Osborne;M Abeloff;G Hortobagyi;DF Hayes;C Ambrosone Breast Cancer Treatment and Research 124(2):433-439;
2009
Treatment quality and outcomes of African American versus Caucasian breast cancer patients: retrospective analysis of Southwest Oncology Group studies S8814-S8897 [PMC2674002; PMID19307504]
D Hershman;J Unger;W Barlow;L Hutchins;S Martino;CK Osborne;RB Livinsgton;KS Albain Journal of Clinical Oncology 27(13):2157-2162
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for breast cancer: results from an ancillary study to Southwest Oncology Group Trial S8897 (INT-0102). [PMC2799053;PMID19752340]
CB Ambrosone;W Barlow;W Reynolds;RB Livingston;IT Yeh;JY Choi;W Davis;JM Rae;L Tang;L Hutchins;PM Ravdin;S Martino;CK Osborne;M Abeloff;AP Lyss;DF Hayes;KS Albain Journal of Clinical Oncology 27(30):4973-4979
Nitric oxide synthase (N0S3) variants and breast cancer survival in a cooperative group trial (SWOG S8897) [PMC2745926; PMID19671875]
J-Y Choi;WE Barlow;KS Albain;C-C Hong;JG Blanco;RB Livingston;W Davis;JM Rae;I-T Yeh;LF Hutchins;PM Ravdin;S Martino;AP Lyss;CK Osborne;M Abeloff;DF Hayes;CB Ambrosone Clinical Cancer Research, 15(16):5258-66, 2009;
2008
Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group (SWOG) protocol S8897 [PMID 18227530]
PA Ganz;MA Hussey;CM Moinpour;JM Unger;LF Hutchins;SR Dakhil;JK Giguere;JW Goodwin;S Martino;KS Albain Journal of Clinical Oncology 26:1223-1230
The Southwest Oncology Group: progress in cancer research [PMID18929152]
CA Coltman Seminars in Oncology 35(5):545-552
2006
Pharmacogenetics and breast cancer treatment outcomes: results on oxidative stress-related genotypes (MPO, MnSOD) from a Southwest Oncology Group intergroup trial (INT-0102)
CB Ambrosone;W Barlow;IT Yeh;DF Hayes;W Davis;JM Rae;LF Hutchins;RB Livingston;PM Ravdin;S Martino;K Osborne;M Abeloff;AP Lyss;KS Albain Breast Cancer Research and Treatment 100(Suppl 1):S18 (#37); oral presentation at SABCS
Outcome of African American women with breast cancer in cooperative group clinical trials
JM Unger;S Green;KS Albain Breast Cancer in Women of African Descent, Ch. 11, pp 267-295, C. Williams et al. (eds.), Springer, printed in Netherlands
Treatment quality and outcome of African American vs. European American breast cancer patients: retrospective analysis of southwest oncology group studies S8814/S8897
D Hershman;J Unger;W Barlow;L Hutchins;S Martino;M Abeloff;L Norton;R Livingston;CK Osborne;K Albain San Antonio Breast Cancer Symposium Proceedings #3049
2005
Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup protocol INT-0102
LF Hutchins;SJ Green;PM Ravdin;D Lew;S Martino;M Abeloff;AP Lyss;C Allred;SE Rivkin;CK Osborne Journal of Clinical Oncology 23(33):8313-8321
Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer.
LJ Pierce;LF Hutchins;SR Green;DL Lew;JR Gralow;RB Livingston;CK Osborne;KS Albain Journal of Clinical Oncology 23(1):24-29
2001
Adjuvant therapy for very young women with breast cancer: need to tailored treatments
A Goldhirsch;RD Gelber;G Yothers;RJ Gray;S Green;J Bryant;S Gelber;M Castiglione-Gertsch;AS Coates Journal of the National Cancer Institute Monographs No.30:44-51
1999
CMF versus CAF with or without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: Update of tamoxifen results
L Hutchins;S Green;P Ravdin;D. Lew;S Martino;M Abeloff;A Lyss;C Henderson;C Allred;S Dakhil;I Pierce;W Goodwin;J Caton;S Rivkin;R Chapman;K Osborne 22nd Annual San Antonio Breast Cancer Symposium :#1
1998
CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: First results of intergroup trial INT 0102.
L Hutchins;S Green;P Ravdin;D Lew;S Martino;M Abeloff;A Lyss;C Henderson;C Allred;S Dakhil;I Pierce;W Goodwin;J Caton;S Rivkin;R Chapman;K Osborne Proc of the American Society of Clinical Oncology 17:1a(#2)
A study of the late cardiac effects of two different adjuvant chemotherapy regimens in women with node negative breast cancer treated on SWOG 8897.
PA Ganz Susan G. Koman Brst Ca Foundation Symp Rpt of Grants Awarded 30:
1996
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: An analysis of two intergroup studies.
KS Albain;SR Green;AS Lichter;LF Hutchins;WC Wood;IC Henderson;JN Ingle;J O'Sullivan;CK Osborne;S Martino Journal of Clinical Oncology 14(11):3009-3017
1994
The influence of patient characteristics, socioeconomic (SES) factors, geography, and systemic risk on the use of breast sparing treatment in adjvant breast cancer studies.
A Lichter;S Green;K Albain;L Hutchins;S Martino ASCO 13:62(#51)
